vs
Orthofix Medical Inc.（OFIX）与ORMAT TECHNOLOGIES, INC.（ORA）财务数据对比。点击上方公司名可切换其他公司
ORMAT TECHNOLOGIES, INC.的季度营收约是Orthofix Medical Inc.的1.3倍（$276.0M vs $219.9M），ORMAT TECHNOLOGIES, INC.净利率更高（11.4% vs -1.0%，领先12.4%），ORMAT TECHNOLOGIES, INC.同比增速更快（19.6% vs 2.0%），Orthofix Medical Inc.自由现金流更多（$16.8M vs $-40.0M），过去两年ORMAT TECHNOLOGIES, INC.的营收复合增速更高（11.0% vs 8.0%）
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
Ormat Technologies是总部位于美国内华达州里诺的跨国企业，主打可再生地热能源技术，累计建成超190座电站，总装机容量超3200兆瓦；截至2021年1月自主运营933兆瓦地热及余热回收电站，还向全球多国供应超千台涡轮增压器。
OFIX vs ORA — 直观对比
营收规模更大
ORA
是对方的1.3倍
$219.9M
营收增速更快
ORA
高出17.7%
2.0%
净利率更高
ORA
高出12.4%
-1.0%
自由现金流更多
OFIX
多$56.9M
$-40.0M
两年增速更快
ORA
近两年复合增速
8.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $219.9M | $276.0M |
| 净利润 | $-2.2M | $31.4M |
| 毛利率 | 71.1% | 28.6% |
| 营业利润率 | 0.2% | 15.4% |
| 净利率 | -1.0% | 11.4% |
| 营收同比 | 2.0% | 19.6% |
| 净利润同比 | 92.4% | -23.2% |
| 每股收益（稀释后） | $-0.05 | $0.51 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OFIXORA
| Q4 25 | $219.9M | $276.0M | ||
| Q3 25 | $205.6M | $249.7M | ||
| Q2 25 | $203.1M | $234.0M | ||
| Q1 25 | $193.6M | $229.8M | ||
| Q4 24 | $215.7M | $230.7M | ||
| Q3 24 | $196.6M | $211.8M | ||
| Q2 24 | $198.6M | $213.0M | ||
| Q1 24 | $188.6M | $224.2M |
净利润OFIXORA
| Q4 25 | $-2.2M | $31.4M | ||
| Q3 25 | $-22.8M | $24.1M | ||
| Q2 25 | $-14.1M | $28.0M | ||
| Q1 25 | $-53.1M | $40.4M | ||
| Q4 24 | $-29.1M | $40.8M | ||
| Q3 24 | $-27.4M | $22.1M | ||
| Q2 24 | $-33.4M | $22.2M | ||
| Q1 24 | $-36.0M | $38.6M |
毛利率OFIXORA
| Q4 25 | 71.1% | 28.6% | ||
| Q3 25 | 72.2% | 25.6% | ||
| Q2 25 | 68.7% | 24.3% | ||
| Q1 25 | 62.8% | 31.7% | ||
| Q4 24 | 69.0% | 31.9% | ||
| Q3 24 | 68.7% | 27.8% | ||
| Q2 24 | 67.8% | 28.8% | ||
| Q1 24 | 67.5% | 35.2% |
营业利润率OFIXORA
| Q4 25 | 0.2% | 15.4% | ||
| Q3 25 | -8.3% | 16.2% | ||
| Q2 25 | -7.9% | 15.1% | ||
| Q1 25 | -25.2% | 22.2% | ||
| Q4 24 | -5.3% | 21.3% | ||
| Q3 24 | -9.6% | 16.8% | ||
| Q2 24 | -12.5% | 16.5% | ||
| Q1 24 | -15.6% | 23.5% |
净利率OFIXORA
| Q4 25 | -1.0% | 11.4% | ||
| Q3 25 | -11.1% | 9.7% | ||
| Q2 25 | -6.9% | 12.0% | ||
| Q1 25 | -27.4% | 17.6% | ||
| Q4 24 | -13.5% | 17.7% | ||
| Q3 24 | -13.9% | 10.4% | ||
| Q2 24 | -16.8% | 10.4% | ||
| Q1 24 | -19.1% | 17.2% |
每股收益（稀释后）OFIXORA
| Q4 25 | $-0.05 | $0.51 | ||
| Q3 25 | $-0.57 | $0.39 | ||
| Q2 25 | $-0.36 | $0.46 | ||
| Q1 25 | $-1.35 | $0.66 | ||
| Q4 24 | $-0.76 | $0.67 | ||
| Q3 24 | $-0.71 | $0.36 | ||
| Q2 24 | $-0.88 | $0.37 | ||
| Q1 24 | $-0.95 | $0.64 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $82.0M | $147.4M |
| 总债务越低越好 | — | $2.7B |
| 股东权益账面价值 | $450.0M | $2.5B |
| 总资产 | $850.6M | $6.2B |
| 负债/权益比越低杠杆越低 | — | 1.05× |
8季度趋势，按日历期对齐
现金及短期投资OFIXORA
| Q4 25 | $82.0M | $147.4M | ||
| Q3 25 | $62.9M | $79.6M | ||
| Q2 25 | $65.6M | $88.5M | ||
| Q1 25 | $58.0M | $112.7M | ||
| Q4 24 | $83.2M | $94.4M | ||
| Q3 24 | $30.1M | $88.1M | ||
| Q2 24 | $26.4M | $66.3M | ||
| Q1 24 | $27.0M | $201.5M |
总债务OFIXORA
| Q4 25 | — | $2.7B | ||
| Q3 25 | $157.2M | — | ||
| Q2 25 | $157.0M | — | ||
| Q1 25 | $156.9M | — | ||
| Q4 24 | $157.0M | $2.3B | ||
| Q3 24 | $118.5M | — | ||
| Q2 24 | $118.0M | — | ||
| Q1 24 | $118.2M | — |
股东权益OFIXORA
| Q4 25 | $450.0M | $2.5B | ||
| Q3 25 | $442.5M | $2.5B | ||
| Q2 25 | $458.3M | $2.5B | ||
| Q1 25 | $458.3M | $2.5B | ||
| Q4 24 | $503.1M | $2.4B | ||
| Q3 24 | $525.9M | $2.4B | ||
| Q2 24 | $546.0M | $2.4B | ||
| Q1 24 | $570.3M | $2.4B |
总资产OFIXORA
| Q4 25 | $850.6M | $6.2B | ||
| Q3 25 | $832.6M | $6.1B | ||
| Q2 25 | $837.2M | $6.0B | ||
| Q1 25 | $823.1M | $5.8B | ||
| Q4 24 | $893.3M | $5.7B | ||
| Q3 24 | $867.9M | $5.6B | ||
| Q2 24 | $882.0M | $5.5B | ||
| Q1 24 | $906.0M | $5.5B |
负债/权益比OFIXORA
| Q4 25 | — | 1.05× | ||
| Q3 25 | 0.36× | — | ||
| Q2 25 | 0.34× | — | ||
| Q1 25 | 0.34× | — | ||
| Q4 24 | 0.31× | 0.97× | ||
| Q3 24 | 0.23× | — | ||
| Q2 24 | 0.22× | — | ||
| Q1 24 | 0.21× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $27.7M | $105.0M |
| 自由现金流经营现金流 - 资本支出 | $16.8M | $-40.0M |
| 自由现金流率自由现金流/营收 | 7.6% | -14.5% |
| 资本支出强度资本支出/营收 | 4.9% | 52.6% |
| 现金转化率经营现金流/净利润 | — | 3.35× |
| 过去12个月自由现金流最近4个季度 | $-1.3M | $-284.7M |
8季度趋势，按日历期对齐
经营现金流OFIXORA
| Q4 25 | $27.7M | $105.0M | ||
| Q3 25 | $12.4M | $45.2M | ||
| Q2 25 | $11.6M | $96.9M | ||
| Q1 25 | $-18.4M | $88.0M | ||
| Q4 24 | $23.7M | $158.6M | ||
| Q3 24 | $11.7M | $106.4M | ||
| Q2 24 | $9.0M | $30.7M | ||
| Q1 24 | $-18.6M | $115.2M |
自由现金流OFIXORA
| Q4 25 | $16.8M | $-40.0M | ||
| Q3 25 | $2.5M | $-102.1M | ||
| Q2 25 | $4.5M | $-37.9M | ||
| Q1 25 | $-25.1M | $-104.6M | ||
| Q4 24 | $15.2M | $30.9M | ||
| Q3 24 | $6.3M | $-3.3M | ||
| Q2 24 | $-360.0K | $-116.1M | ||
| Q1 24 | $-29.1M | $11.8M |
自由现金流率OFIXORA
| Q4 25 | 7.6% | -14.5% | ||
| Q3 25 | 1.2% | -40.9% | ||
| Q2 25 | 2.2% | -16.2% | ||
| Q1 25 | -13.0% | -45.5% | ||
| Q4 24 | 7.0% | 13.4% | ||
| Q3 24 | 3.2% | -1.6% | ||
| Q2 24 | -0.2% | -54.5% | ||
| Q1 24 | -15.4% | 5.3% |
资本支出强度OFIXORA
| Q4 25 | 4.9% | 52.6% | ||
| Q3 25 | 4.8% | 59.0% | ||
| Q2 25 | 3.5% | 57.6% | ||
| Q1 25 | 3.5% | 83.8% | ||
| Q4 24 | 4.0% | 55.4% | ||
| Q3 24 | 2.7% | 51.8% | ||
| Q2 24 | 4.7% | 69.0% | ||
| Q1 24 | 5.6% | 46.1% |
现金转化率OFIXORA
| Q4 25 | — | 3.35× | ||
| Q3 25 | — | 1.87× | ||
| Q2 25 | — | 3.45× | ||
| Q1 25 | — | 2.18× | ||
| Q4 24 | — | 3.89× | ||
| Q3 24 | — | 4.82× | ||
| Q2 24 | — | 1.38× | ||
| Q1 24 | — | 2.99× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
ORA
| Electricity | $186.6M | 68% |
| Products | $63.1M | 23% |
| Energy Storage Segment | $26.3M | 10% |
| Product Segment | $1.2M | 0% |
